PharmaRadar360

PharmaRadar360

🌍·Aug 25discovery

Merck and Moderna announced on 19 August 2026 that a personalised mRNA cancer vaccine had succeeded in a Phase 3 trial β€” the first time a vaccine built from a patient's own tumour mutations has cleared that bar in the history of oncology

Publisher

S
ScienceBlog.com

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
ScienceBlog.com
Region
Global
Scope
discovery
Published
August 25, 2026
Language
EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: ScienceBlog.com

Scope: discovery

Open original article
Merck and Moderna announced on 19 August 2026 that a personalised mRNA cancer vaccine had succeeded in a Phase 3 trial β€” the first time a vaccine built from a patient's own tumour mutations has cleared that bar in the history of oncology | PharmaRadar360